Tomohiro Handa1, Shoko Matsui2, Hajime Yoshifuji3, Yuzo Kodama4, Hiroshi Yamamoto5, Seijiro Minamoto6, Yuko Waseda7, Yasuharu Sato8, Keishi Kubo9, Tsuneyo Mimori3, Tsutomu Chiba4,10, Toyohiro Hirai1, Michiaki Mishima11. 1. a Department of Respiratory Medicine, Graduate School of Medicine , Kyoto University , Kyoto , Japan. 2. b Health Administration Center , University of Toyama , Toyama , Japan. 3. c Department of Rheumatology and Clinical Immunology, Graduate School of Medicine , Kyoto University , Kyoto , Japan. 4. d Department of Gastroenterology and Hepatology, Graduate School of Medicine , Kyoto University , Kyoto , Japan. 5. e First Department of Internal Medicine , Shinshu University School of Medicine , Nagano , Japan. 6. f Department of Medicine for Allergic Diseases , Osaka Habikino Medical Center , Osaka , Japan. 7. g Third Department of Internal Medicine, Faculty of Medical Sciences , University of Fukui , Fukui , Japan. 8. h Department of Pathology , Okayama University Grduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama , Japan. 9. i Nagano Prefectural Hospital Organization , Nagano , Japan. 10. j Kansai Electric Power Hospital , Osaka , Japan. 11. k Department of Respiratory Medicine , Saiseikai-Noe Hospital , Osaka , Japan.
Abstract
OBJECTIVES: Serum soluble interleukin-2 (IL-2) receptor (sIL-2R) might reflect disease activity in immunoglobulin G4-related disease (IgG4-RD). We aimed to elucidate the clinical significance of blood markers, including sIL-2R, in patients with IgG4-RD. METHODS: We enrolled 59 patients with IgG4-RD and investigated the association between blood markers (white blood cells, C-reactive protein, sIL-2R, IgG, IgG4, IgE, total hemolytic complement), and clinical indices. RESULTS: At baseline, serum sIL-2R (Rs = 0.532, p < .001) and IgG4 (Rs = 0.545, p < .001) levels showed significant correlation to the number of organs involved. During follow-up period (median, 70 months; range, 7-195 months), 40 patients were treated with corticosteroids. Receiver operating characteristic (ROC) analysis showed that baseline sIL-2R levels most accurately predicted patients requiring glucocorticoid treatment (area under the ROC curve, 0.807). Among the 46 patients who improved, sIL-2R and IgG4 levels decreased in 42 and 41 patients, respectively. Among them, serum sIL-2R levels decreased to a normal range in 42 patients (91%), whereas IgG4 levels normalized in 19 (41%). CONCLUSION: The serum sIL-2R level is a potential biomarker for IgG4-RD that may reflect the number of involved organs and may predict patients requiring glucocorticoid treatment.
OBJECTIVES: Serum soluble interleukin-2 (IL-2) receptor (sIL-2R) might reflect disease activity in immunoglobulin G4-related disease (IgG4-RD). We aimed to elucidate the clinical significance of blood markers, including sIL-2R, in patients with IgG4-RD. METHODS: We enrolled 59 patients with IgG4-RD and investigated the association between blood markers (white blood cells, C-reactive protein, sIL-2R, IgG, IgG4, IgE, total hemolytic complement), and clinical indices. RESULTS: At baseline, serum sIL-2R (Rs = 0.532, p < .001) and IgG4 (Rs = 0.545, p < .001) levels showed significant correlation to the number of organs involved. During follow-up period (median, 70 months; range, 7-195 months), 40 patients were treated with corticosteroids. Receiver operating characteristic (ROC) analysis showed that baseline sIL-2R levels most accurately predicted patients requiring glucocorticoid treatment (area under the ROC curve, 0.807). Among the 46 patients who improved, sIL-2R and IgG4 levels decreased in 42 and 41 patients, respectively. Among them, serum sIL-2R levels decreased to a normal range in 42 patients (91%), whereas IgG4 levels normalized in 19 (41%). CONCLUSION: The serum sIL-2R level is a potential biomarker for IgG4-RD that may reflect the number of involved organs and may predict patients requiring glucocorticoid treatment.
Authors: H H S Kharagjitsing; T R Hendriksz; M A Fouraux; T van Gelder; E F H van Bommel Journal: Int Urol Nephrol Date: 2022-03-31 Impact factor: 2.266
Authors: Ji Zongfei; Zhang Lijuan; Sun Ying; Liu Dongmei; Wu Sifan; Kong Xiufang; Ma Lingying; Liu Yun; Ma Lili; Chen Huiyong; Jiang Lindi Journal: Ther Adv Chronic Dis Date: 2021-06-30 Impact factor: 5.091